Comparative Pharmacology
Head-to-head clinical analysis: RENESE R versus SALUTENSIN DEMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENESE R versus SALUTENSIN DEMI.
RENESE-R vs SALUTENSIN-DEMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination